| Document |
Document Title |
|
WO/2019/092170A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising as-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing...
|
|
WO/2019/087983A1 |
Provided is a benzotriazole compound that efficiently absorbs UV rays having a long wavelength of 360-400 nm, and either i) has excellent solubility in a monomer of a resin raw material and can dissolve at a high concentration, polymeriz...
|
|
WO/2019/089724A1 |
Disclosed in certain embodiments is a lubricating grease composition comprising an antioxidant polymer (e.g., oligomer) composition comprising repeat units of diphenylamine monomers of formula (I) wherein R is H, C1-C18 alkyl, C2-C18 alk...
|
|
WO/2019/086494A1 |
Provided are compounds having the general formula I: wherein R1, R B1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds. The compound...
|
|
WO/2019/089723A1 |
Disclosed in certain embodiments is a lubricating oil composition comprising an antioxidant polymer (e.g., oligomer) composition comprising repeat units of diphenylamine monomers of formula (I) wherein R is H, C1-C18 alkyl, C2-C18 alkeny...
|
|
WO/2019/090078A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/080926A1 |
Disclosed are a benzotriazole ultraviolet absorber and a preparation method therefor, a polymer comprising the benzotriazole ultraviolet absorber, and the use thereof. The benzotriazole ultraviolet absorber has an excellent ultraviolet a...
|
|
WO/2019/080868A1 |
The present subject matter relates to water-soluble, fluorescent compounds that have aggregation-induced emission (AIE) characteristics and exhibit near infrared (NIR) absorption. The compounds can be utilized as plasma-membrane specific...
|
|
WO/2019/069960A1 |
A compound shown in general formula (I-1). (In the formula, A represents an atom group having ultraviolet light absorption capacity, B represents a photoelimination group, and k represents an integer from 1 to 10). A composition containi...
|
|
WO/2019/069549A1 |
A liquid-crystal composition which contains a specific ultraviolet absorber as a first additive and which may contain a specific compound having a low viscosity or a high upper-limit temperature as a first ingredient, a specific compound...
|
|
WO/2019/062665A1 |
The present invention discloses a linker compound, a polyethylene glycol-linker conjugate and a derivative thereof, and a polyethylene glycol-linker drug conjugate. The linker compound and the polyethylene glycol conjugate and a derivati...
|
|
WO/2019/057969A1 |
The present invention relates to small molecule compounds and their use as agonists of farnesoid X receptor (FXR) and/or peroxisome proliferator activated receptor delta (PPARδ). The present invention also relates to the use of said com...
|
|
WO/2019/059132A1 |
The purpose of the present invention is to provide a novel NF-κB inhibitor which has a more effective and higher bioavailability and is more suitable for clinical application. More specifically, the purpose of the present invention is t...
|
|
WO/2019/053090A1 |
The present disclosure provides a compound of formula (I): (I); or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treatin...
|
|
WO/2019/054430A1 |
The purpose of the present invention is to provide a compound having an anti-inflammatory action, a pharmacologically acceptable salt thereof, etc. A solving means of the present invention is a compound of general formula (1) or a pharma...
|
|
WO/2019/054427A1 |
The present invention addresses the problem of providing a compound having an anti-inflammatory effect, a pharmacologically acceptable salt thereof, etc. The means for solution according to the present invention is a compound represented...
|
|
WO/2019/051396A1 |
Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR...
|
|
WO/2019/045085A1 |
The present invention provides 1-(N,N-disubstituted carbamoyl) 4-(substituted sulfonyl)triazolin-5-one derivatives represented by general formula 1 and 4-(N,N-disubstituted carbamoyl) 1-(substituted sulfonyl)triazolin-5-one derivatives r...
|
|
WO/2019/034729A1 |
The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, ...
|
|
WO/2019/034690A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group ...
|
|
WO/2019/034692A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of...
|
|
WO/2019/031240A1 |
The present invention makes it possible to obtain a compound represented by formula (II) at a high yield by executing: a step A for obtaining a trimethyl oxosulfonium ylide solution or a trimethyl sulfonium ylide solution by reacting a b...
|
|
WO/2019/025467A1 |
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful fo...
|
|
WO/2019/022179A1 |
To provide a heterocyclic compound which can exhibit an antagonistic action to NR2B subunit-containing NMDA receptors and, therefore, is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder,...
|
|
WO/2019/016115A1 |
The present invention relates to a process for providing substituted aryl ketones.Furthermore, the invention relates to intermediates of said process and the use of substituted aryl ketones obtained by the inventive process for the prepa...
|
|
WO/2019/015794A1 |
The present invention relates to a chemical compound according to general formula (1).
|
|
WO/2019/016385A1 |
The present invention relates to benzamide compounds of the formula (I) and the N-oxides and salts thereof and to compositions comprising the same. The variables are as defined in the claims and the description. The invention also relate...
|
|
WO/2019/016637A1 |
The present invention provides an improved process for the preparation of Deferasirox of Formula - I substantially free from 'hydrazino impurity' by the condensation of 2-(2-hydrophenyl)-4H-1,3-benzoxazin-4-one of Formula - IV with 4-hyd...
|
|
WO/2019/010201A1 |
In one embodiment, the invention' provides a chimeric antigen receptor (CAR) T cell which is conjugated to a bi-functional molecule which is specific for both an extracellular binding domain of the chimeric antigen receptor (CAR) T cell ...
|
|
WO/2017/161293A9 |
Described herein are polycatenar ligand compounds and their use in the production of hybrid nanoparticles, typically nanocrystals. The present disclosure also relates to films containing the hybrid nanoparticles described herein and thei...
|
|
WO/2019/006750A1 |
A reactive ultraviolet absorber applicable to polyurethane, and in particular, a compound as represented by a chemical formula (1), wherein R1 is H or Cl.
|
|
WO/2019/002971A1 |
Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxybiphenyl benzotriazole structures with polymerizable functionality that block high energy light and a...
|
|
WO/2019/001325A1 |
The present invention relates to a new crystal form of lesinurad, a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in the preparation of a uric acid transporter inhibito...
|
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/236115A1 |
The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when...
|
|
WO/2018/230528A1 |
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...
|
|
WO/2018/229027A1 |
The present invention relates to a process for the preparation of the compounds of formula (II) using a lanthanoid salt.
|
|
WO/2018/224455A1 |
The invention relates to cyclopropyl compounds of formula (I), wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use fo...
|
|
WO/2018/219935A1 |
The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4 (formulae (Q1), (Q2), (Q3), (Q4)); and their use as herbicides. In said formula (I), R2 is R2cR2dNC(O)NR2n-Z2, both R4 and R5 are hydrogen, R1, R3 and ...
|
|
WO/2018/219936A1 |
The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4, and their use as herbicides. In said formula (I), R2 is R2cR2dNC(O)NR2n-Z2, R5 is hydrogen, R1, R3, R4 and R6 represent groups such as hydrogen, halog...
|
|
WO/2018/215818A1 |
The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and...
|
|
WO/2018/216823A1 |
Provided are novel compounds represented by the following general formula [1] or pharmaceutically acceptable salts thereof, that inhibit LpxC, as well as pharmaceutical drugs comprising those compounds or pharmaceutically acceptable salt...
|
|
WO/2018/218093A1 |
The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload compri...
|
|
WO/2018/211532A1 |
The present invention provides novel solid state forms of 2-((5-bromo-4-(4- cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)aceti
c acid of formula (I) namely crystalline Form-M, crystalline Form-S, crystalline Form-N, crystalline...
|
|
WO/2018/210354A1 |
A novel preparation method for the anti-gout drug lesinurad, and a key intermediate thereof. The method comprises the following reaction steps: 1) the compound of formula II undergoing a substitution reaction with R3-SH in the presence o...
|
|
WO/2018/202689A1 |
The present invention relates to a process for the preparation of particular 2-(2H-[1,2,3]triazol-2-yl)-benzoic acid derivatives of formula (I), to certain crystalline forms of potassium salts of said 2-(2H-[1,2,3]triazol-2-yl)-benzoic a...
|
|
WO/2018/199562A1 |
The present invention relates to a 2-amino-2-(1-(2-(2-hydroxyethoxy)ethyl)-1H-1,2,3-triazole-4-
yl)propane-1,3-diol derivative which is a novel compound represented by chemical formula 1, and a use thereof. The novel compound of chemical...
|
|
WO/2018/193385A1 |
The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to metho...
|
|
WO/2018/190281A1 |
Provided are benzotriazole derivative compounds of the general formula that are novel compounds capable of strongly absorbing light in the ultraviolet range, particularly 300-330 nm, while strongly absorbing light in the visible light sh...
|
|
WO/2018/189340A1 |
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (...
|
